News about Drug Discovery & Development

Biocon Biologics Signs License Deal with Janssen for Bmab 1200

Under the terms of this settlement agreement, Biocon Biologics has resolved patent disputes with Janssen to secure market entry dates in Europe, the UK, Canada, and Japan. Regulatory filings in these markets are currently under review.

Drug Discovery & Development | 29/08/2024 | By Aishwarya |  504

Alembic Gets FDA Approval for Betamethasone Valerate Foam

Betamethasone valerate foam, 0.12 percent, is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.

Drug Discovery & Development | 27/08/2024 | By Aishwarya |  493

BioIVT Acquires ZenBio to Expand its Pharmaceutical Portfolio

Together, BioIVT and ZenBio will offer an expanded portfolio of skin-based expertise, primary cell and exosome isolation, as well as blood products for pharmaceutical and cosmetics companies.

Drug Discovery & Development | 26/08/2024 | By Aishwarya |  396

Sun Pharma Launches a Tedizolid Phosphate Tablets in India

STARIZO (Tedizolid Phosphate) is a novel, oxazolidinone-class antibacterial, used to treat Acute Bacterial Skin and Skin Structure Infection (ABSSSI).

Drug Discovery & Development | 26/08/2024 | By Aishwarya |  949

RedHill Biopharma Announces Roll Out of Talicia in UAE

The commercial launch of Talicia in the UAE triggers RedHill's eligibility for additional potential milestone payments, minimum sales payments and tiered royalties up to mid-teens on net sales.

Drug Discovery & Development | 23/08/2024 | By Aishwarya |  1124

Bridge Biotherapeutics and HitGen to Advance Novel Cancer Therapeutics Program

Bridge plans to strengthen its existing oncology portfolio, which is centered on EGFR inhibitors for lung cancer treatment, through new anticancer drug candidates targeting undisclosed targets.

Drug Discovery & Development | 23/08/2024 | By Aishwarya |  547

Clarity Secures FDA Fast Track Designation for 64Cu-SAR-bisPSMA

Clarity Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation for 64Cu-SAR-bisPSMA for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive prostate cancer lesions.

Drug Discovery & Development | 23/08/2024 | By Aishwarya |  293

Dr. Reddy's, Aurigene and Kainomyx to Jointly Develop Affordable Anti-Malarial Drug

Under the MoU, Kainomyx has agreed to lead the technical strategy and associated aspects for drug discovery and clinical phases, Aurigene has agreed to focus on developing cost-effective and scalable drug chemistry, and while the program evolves, Dr. Reddy’s will bring in its regulatory and market access expertise.

Drug Discovery & Development | 22/08/2024 | By Aishwarya |  476

BerGenBio Partners with Tempus to Accelerate Development in STK11m Non-Small Cell Lung Cancer

BerGenBio's on-going BGBC016 Phase 1b/2a trial is designed to assess the benefit of adding bemcentinib to the current standard of care treatment (immunotherapy + doublet chemotherapy) in 1L STK11m patients, a population with poor outcomes and no specific therapies today.

Drug Discovery & Development | 21/08/2024 | By Aishwarya |  602

Glenmark Therapeutics Unveils Olopatadine Hydrochloride Ophthalmic Solution

Glenmark Therapeutics has launched Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 percent (OTC) as compared to the active ingredient in Pataday Twice Daily Relief.

Drug Discovery & Development | 20/08/2024 | By Aishwarya |  609